FMP
Regnum Corp.
RGMP
PNK
Inactive Equity
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
0.0001 USD
-0.0082 (-8200%)
About
ceo
Mr. Robert J. Stubblefield CPA
sector
Healthcare
industry
Biotechnology
website
N/A
exchange
PNK
Description
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company is based in New York, New York. Regnum Corp. is a subsidiary of Phoenixus AG.
CIK
0001716324
ISIN
US75915R1068
CUSIP
75915R106
Address
600 Third Avenue
Phone
877 313 2232
Country
US
Employee
1
IPO Date
May 29, 2019
Summary
CIK
0001716324
Exchange
PNK
Industry
Biotechnology
Sector
Healthcare
CUSIP
75915R106
ISIN
US75915R1068
Country
US
Price
0
Beta
2.79
Volume Avg.
4.5k
Market Cap
2.29k
Shares
-
52-Week
0.0059-0.8
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
-
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RGMP News
It looks like there's no news available.
